2. Asking L, Malmqvist Granlund K, Lindblad T. An In-Vitro comparison of two dry powder inhalers; Symbicort® Turbuhaler® and Seretide™ Diskusand Seretide™ Diskus. Am J Respir Crit Care Med 2001;163(Suppl 5):A441 + poster.

3. Buhl R, Creemers JPHM, Vondra V, Martelli NA. Once-daily budesonide/formoterol via a single inhaler is effective in mild-to-moderate persistent asthma. Eur Respir J 2001; 18(Suppl 33):21s.

4. Bateman ED, Bantje TA, Joao GM, Toumbis M, Huber R, Eliraz A, Pettersson E. Symbicort® (budesonide and formoterol in a single inhaler) is a more effective treatment than fluticasone in asthma patients. Am J Respir Crit Care Med 2001;163(Suppl 5):A865 + poster.

5. Brown PH, Ning AC, Greening AP, McLean A, Crompton GK. Peak inspiratory flow through Turbuhaler® in acute asthma. Eur Respir J 1995;8:1940-1.

6. Busse WW, Chervinsky P, Condemi J, Lumry WR, Petty TL, Rennard S, Townley RG. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998; 101(4 Pt 1): 457-63

7. Crompton GK, Dewar MH, Allbutt HM, Innes JA. Inhaler preference and technique in inhaler naïve subjects; A comparison of HFA and conventional devices. Thorax 2000; 55 (Suppl 3): A61

8. Engel T, Scharling B, Skovsted B, Heinig JH. Effects, side effects and plasma concentrations of terbutaline in adult asthmatics after inhaling from a dry powder inhaler device at different inhalation flows and volumes. Brit J Clin Pharm 1992;33:439-44.

9. Ericsson K, Bantje TA, Huber R, Borg S, Andersson F. Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma. Eur Respir J 2001; 18(Suppl 33):157s.

10. IMS Health 2000 – MAT Q3/00

11. Kemp JP, Chervinsky P, Nelson H. A randomised, double-blind, placebo controlled, dose-response study with formoterol Turbuhaler. J Allergy Clin Immunol 1997; 99:S329.

12. Kips JC, O'Connor BJ, Inman MD, Svensson K, Pauwels RA, O'Byrne PM. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161: 996-1001

13. Lindblad T, Malmqvist Granlund K, Rollwage U, Trofast E. Delivery characteristics of Symbicort® Turbuhaler® containing both budesonide and formoterol. Am J Respir Crit Care Med 2001;163(Suppl 5):A863 + poster.Miller Larsson Anna, Jansson P, Runstrom A, Brattsand R. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am J Respir Crit Care Med 2000;162(4 Part 1):1455-61

15. Miller-Larsson A, Mattsson H, Hjertberg E, Dahlbäck M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide: Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998; 26(7):623-30Palmqvist M, Arvidsson P, Beckman O, Peterson S, Lötvall J. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticason in single inhalers. Pulm Pharmacol Ther 2001; 14(1):29-42.

17. Palmqvist M, Ibsen T, Mellén A, Lötvall J. Salmeterol is a partial -agonist in relation to formoterol in asthmatic patients. Eur Respir J 1999;14(Suppl 30):327s

18. Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J 1999; 13(5): 988-992

19. Rosenhall L, Ericsson K, Borg S, Andersson F. Healthcare costs are reduced when asthma is treated with budesonide and formoterol in a single inhaler compared with the same medication via separate inhalers. Eur Respir J 2001; 18(Suppl 33):54s+poster

20. Schreurs AJ, Sinninghe Damste HE, de Graaff CS, Greefhorst AP. A dose-response study with formoterol Turbuhaler as maintenance therapy in asthmatic patients. Eur Respir J 1996; 9(8): 1678-83

21. Seberová E, Andersson A. Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med 2000;94(6):607-11

22. Ståhl E, Ribeiro LB, Sandahl G. Dose response to inhaled terbutaline powder and peak inspiratory flow through Turbuhaler® in children with mild to moderate asthma. Pediatr Pulmonol. 1996; 22:106-10.

23. Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, O'Byrne PM, Löfdahl CG, Pauwels RA, Ullman A. Exacerbations of asthma - a descriptive study of 425 exacerbations. Am J Respir Crit Care Med 1999;160:594-9

24. Tattersfield AE, Löfdahl CG, Postma DS, Eivindson A, Schreurs AGM, Rasidakis A, Ekström T. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001, Vol 357: 257-61

25. Tötterman KJ, Huhti L, Sutinen E, Backman R, Pietinalho A, Falck M, Larsson P, Selroos O. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. Eur Respir J 1998; 12 (3): 573-579

26. Zetteström O, Buhl R, Mellen H, Perpiña M, Hedman J, O’Neill S, et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001; 18(2):262-268.

27. Zetterström O, Buhl R, Mellem H, Perpiña M, Hedman J, O'Neill S, Peterson S. Symbicort (budesonide/formoterol in a single inhaler) improves asthma control and exacerbations rate in adult patients. Allergy 2001; 56(Suppl 68):281+poster.